Sign in
Taking peopleNo phase

Real-world study of JAK inhibitor medicines for alopecia areata

Looks at how well JAK inhibitors work and their safety in alopecia areata.

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Status
Recruiting
People taking part
150 people, planned
Started
29 Jul 2024
Expected to end
31 Dec 2026
Type of study
Observational, 6 groups
Treatments tested
  • Tofacitinib
  • Baricitinib
  • Ruxolitinib
  • Upadacitinib
  • Abrocitinib
  • Ritlecitinib
Record updated
27 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with alopecia areata (patchy hair loss) who have been treated with a JAK inhibitor medicine for more than 3 months.

Age
The criteria say 2 to 18 years old. The record also lists an age range of 2 Years to 80 Years.
Sex
All sexes can join.
Disease stage
Alopecia areata diagnosed according to the AA guideline.
Earlier treatment
Must have been treated for more than 3 months with a JAK inhibitor: tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib or ifidancitinib.

Main reasons for not taking part

  • Hair implants received before
  • Another type of hair loss
  • Other diseases that can cause hair loss, such as psoriasis or lichen planus
  • Hair loss score (SALT score) cannot be measured at the start or at follow-up
  • Taking part in other clinical trials

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients with alopecia areata between 2 to 18 years old
  • Patients diagnosed with alopecia areata according to AA guideline
  • AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months

Who cannot take part

  • Patients had previously received hair implants
  • Other diseases may induce alopecia including psoriasis, lichen planus, et al
  • Other alopecia
  • Unable to estimate SALT score at baseline or at follow-up
  • Patients are participating in other clinical trials

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 2 and 80 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

The 6 groups in the trial

  • Tofacitinib treated group

    In the real-world settings, patients with AA treated with tofacitinib.

    Treatment: Tofacitinib

  • Baritinib treated group

    In the real-world settings, patients with AA treated with baritinib.

    Treatment: Baricitinib

  • Ruxolitinib treated group

    In the real-world settings, patients with AA treated with ruxolitinib

    Treatment: Ruxolitinib

  • Upadacitinib treated group

    In the real-world settings, patients with AA treated with upadacitinib.

    Treatment: Upadacitinib

  • Abrocitinib treated group

    In the real-world settings, patients with AA treated with abhicitinib.

    Treatment: Abrocitinib

  • Ritlecitinib treated group

    In the real-world settings, patients with AA treated with ritlecitinib.

    Treatment: Ritlecitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
Plain-language title
Real-world study of JAK inhibitor medicines for alopecia areataGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06573593, who can take part
Record updated
27 August 2024